- Companies
- Oxurion
Oxurion Valuation Multiples
Oxurion is valued at $204K as of November 2026, a 21.4x revenue multiple. In the last fiscal year, Oxurion revenue was $610K and Oxurion EBITDA was ($4M).
Oxurion Overview
About Oxurion
Oxurion NV is a holding company specializing in acquiring and integrating clinical research services companies (CROs) covering the full clinical research value chain across Europe.
Founded
2006
HQ
Employees
26
Website
Sectors
Financials (Last FY)
EV
$13M
Valuation Multiples
Start free trialOxurion Financials
Oxurion reported last fiscal year revenue of $610K and negative EBITDA of ($4M).
In the same fiscal year, Oxurion generated $610K in gross profit, ($4M) in EBITDA losses, and had net loss of ($4M).
Oxurion P&L
In the most recent fiscal year, Oxurion reported revenue of $610K and EBITDA of ($4M).
Oxurion is unprofitable as of last fiscal year, with gross margin of 100%, EBITDA margin of (652%), and net margin of (672%).
Financial data powered by Morningstar, Inc.
Oxurion Stock Performance
Oxurion has current market cap of $204K, and enterprise value of $13M.
Market Cap Evolution
Oxurion's stock price is $0.00.
Oxurion share price decreased by 1.6% in the last 30 days, and by 92.7% in the last year.
Oxurion has an EPS (earnings per share) of $-0.02.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $13M | $204K | 33.2% | -1.6% | -70.9% | -92.7% | $-0.02 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialOxurion Valuation Multiples
Oxurion trades at 21.4x EV/Revenue multiple, and (3.3x) EV/EBITDA.
Oxurion Financial Valuation Multiples
As of November 19, 2026, Oxurion has market cap of $204K and EV of $13M.
Oxurion has a P/E ratio of (0.0x).
Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Oxurion Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.


Oxurion Margins & Growth Rates
In the most recent fiscal year, Oxurion reported gross margin of 100%, EBITDA margin of (652%), and net margin of (672%).
Oxurion Margins
Oxurion Growth Rates
Data powered by FactSet, Inc. and Morningstar, Inc.
Oxurion Operational KPIs
Oxurion's revenue per employee in the last FY averaged $0.0M, while opex per employee averaged $0.2M for the same period.
Data powered by FactSet, Inc. and Morningstar, Inc.
Oxurion Competitors
Oxurion competitors include Magle Chemoswed Holding, BioXcel Therapeutics, bioXXmed, CERo Therapeutics Holdings, Branded Legacy, China SXT Pharmaceuticals, Evofem Biosciences, Ocean Biomedical, Lyra Therapeutics and Vaxxinity.
Most Oxurion public comparables operate across Biopharmaceuticals and BioTech.
| Last FY | EV/Revenue | EV/EBITDA | ||||||
|---|---|---|---|---|---|---|---|---|
| Revenue | EBITDA | Last FY | LTM | 2027E | Last FY | LTM | 2027E | |
| $27M | ($6M) | 1.3x | 1.2x | (6.1x) | (47.9x) | |||
| $642K | ($54M) | 143.1x | 143.1x | (1.7x) | (1.8x) | |||
| $19K | ($416K) | 21.9x | - | (1.0x) | - | |||
| - | ($19M) | - | - | (0.1x) | - | |||
| $64K | ($314K) | 1.8x | - | (0.4x) | - | |||
| $1M | ($6M) | - | - | - | - | |||
| $20M | $1M | 3.0x | - | 59.9x | - | |||
| - | ($7M) | - | - | (0.0x) | - | |||
This data is available for Pro users. Sign up to see all Oxurion competitors and their valuation data. Start Free Trial | ||||||||
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Oxurion
| When was Oxurion founded? | Oxurion was founded in 2006. |
| Where is Oxurion headquartered? | Oxurion is headquartered in Belgium. |
| How many employees does Oxurion have? | As of today, Oxurion has over 26 employees. |
| Who is the CEO of Oxurion? | Oxurion's CEO is Pascal Ghoson. |
| Is Oxurion publicly listed? | Yes, Oxurion is a public company listed on Euronext Brussels. |
| What is the stock symbol of Oxurion? | Oxurion trades under OXUR ticker. |
| When did Oxurion go public? | Oxurion went public in 2006. |
| Who are competitors of Oxurion? | Oxurion main competitors include Magle Chemoswed Holding, BioXcel Therapeutics, bioXXmed, CERo Therapeutics Holdings, Branded Legacy, China SXT Pharmaceuticals, Evofem Biosciences, Ocean Biomedical, Lyra Therapeutics, Vaxxinity. |
| What is the current market cap of Oxurion? | Oxurion's current market cap is $204K. |
| What is the current revenue of Oxurion? | Oxurion's last fiscal year revenue is $610K. |
| What is the current EV/Revenue multiple of Oxurion? | Current revenue multiple of Oxurion is 21.4x. |
| Is Oxurion profitable? | No, Oxurion is not profitable. |
| How many companies Oxurion has acquired to date? | Oxurion hasn't acquired any companies yet (or none have been disclosed publicly). |
| In how many companies Oxurion has invested to date? | Oxurion hasn't invested in any companies yet (or none have been disclosed publicly). |
See public comps similar to Oxurion
Lists including Oxurion
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.




